Introduction
============

Radical prostatectomy (RP) and radiotherapy (RT) are the two primary nonconservative therapeutic options for men diagnosed with clinically localized prostate cancer (PCa). As the two most common forms of RT, external beam radiotherapy (EBRT) and brachytherapy (BT) are chosen by 11.6% and 13.3% of PCa patients in the US, respectively.[@b1-cmar-11-587]

Through survival benefit, however, RT has been associated with various adverse effects including pelvic pain, lower urinary tract symptoms (ie, dysuria, frequency, urgency, incontinence, and hematuria), and rectal symptoms (ie, tenesmus, mucus, hematochezia, fistula, ulceration, and necrosis).[@b2-cmar-11-587]

As the adjacent organs of the prostate, ie, bladder and rectum, are vulnerable to ionizing radiation inescapably. Accumulated data from clinical studies have suggested that a specific complication for PCa patients undergoing RT is the probability of elevated risk of a second primary bladder cancer (BLCa).[@b3-cmar-11-587],[@b4-cmar-11-587] It has long been accepted that this potential association between RT and secondary BLCa might attribute to a prostate metastatic lesion invading the bladder by the radiation scatter and radiation-induced genetic alterations.[@b5-cmar-11-587],[@b6-cmar-11-587] However, some investigators did not support this association; they failed to find an increased risk of secondary BLCa after RT.[@b7-cmar-11-587],[@b8-cmar-11-587]

Currently, a number of more recent publications have continually struggled to address this relationship. Nevertheless, the evidence for this potential connection is still controversial. We have therefore attempted to investigate whether RT was a risk factor for secondary BLCa. We elected to use a meta-analysis of all the available data to better answer this question.

Materials and methods
=====================

This meta-analysis was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. PRISMA checklist was shown in [Table S1](#SD3-cmar-11-587){ref-type="supplementary-material"}. The protocol for this meta-analysis was available from PROSPERO (CRD42018090075; <http://www.crd.york.ac.uk/PROSPERO>).

Search strategy
---------------

MEDLINE (PubMed), Cochrane Library, and the Embase were systematically searched from the inception of the databases to February 12, 2018. The search was restricted to English language and human participants. Subject headings and the text keywords were used for the search. The search strategy was illustrated in the [Supplementary materials section](#SD1-cmar-11-587){ref-type="supplementary-material"}. Data extraction was performed by two authors independently. Disagreements were resolved by consensus with a third author.

Study selection
---------------

We included all of the available epidemiologic evidence that reported the patients who received RT developing secondary BLCa compared with those patients who received RP treatment, or those not treated with RT. On the basis of patient, intervention, comparison, outcome, and study design (PICOS), the question that guided this meta-analysis was: does RT for PCa increase the risk of secondary BLCa? The PICOS evidence base used consisted of the following combinations: clinically localized PCa patients (P); a history of RT for PCa, all types of RT were included (ie, EBRT, BT) (I); compared with the PCa patients with RP treatment or no EBRT (C); the diagnosis of secondary BLCa (O). We accepted all study designs (S). In addition, studies on the pertinent subjects, which provided HR estimates with 95%CIs or adequate data to allow calculation of these effect measures. The exclusion criteria included the following: (1) studies without examining the research question or that do not meet inclusion criteria; (2) without the control groups data or inappropriate grouping (RP combining RT was excluded); (3) review articles, meeting abstracts, comments, editorials, letters, case reports, or congress reports; (4) insufficient outcome data; (5) duplicated or updated data; (6) nonclinical studies, (7) studies with \<10 participants in either the exposure or the control group. For multiple publications of the same clinical trial, only the most recent or representative study was included.

Data extraction
---------------

Two authors (SKZ and JMW) independently extracted the following data: the first authors' names, year of the publication, study regions, data source (study interval), study design, follow-up, age, sample sizes, HR, and survival information. Previous studies defined the radiation-induced secondary cancer occurring after 5 years of radiation exposure, thus we also recorded the length of the lag period from the time of treatment to the confirmation of secondary BLCa among the included studies.

Quality assessment and the overall quality of the evidence
----------------------------------------------------------

The methodological quality assessment of the cohort study was based on the Newcastle--Ottawa Scale (NOS). In this meta-analysis, article quality of cohort study was assessed as follows: low quality =0--3, moderate quality =4--6, high quality =7--9. The GRADE approach was applied to generate absolute estimates of the risk of BLCa in patients who received RT for PCa, evaluate and rank the overall quality of the evidence.

Statistical analyses
--------------------

The strength of association between EBRT for PCa and the risk of secondary BLCa in the included studies was estimated using hazard ratio and its 95%CI. Results with a two-tail *P*-values \<0.05 were considered statistically significant. The heterogeneity of included studies was measured by using the Cochrane *Q* statistic and the *I*^2^ statistic (*I*^2^ \>50% was regarded to be consistent with substantial heterogeneity; *P*-value of *Q* test \<0.10 was considered statistically significant). Owing to the high likelihood of between-study variance for differences in study design as well as the study population, a random effects model rather than a fixed effects model was applied in the current study. Subgroup analyses were performed to further detect the origin of heterogeneity. We also conducted the sensitivity analyses by dropping one included study in each analysis to evaluate the individual impact on the overall pooled result. Publication bias analysis was evaluated with Begg's and Egger's tests. The statistical analysis in the present study was performed using the Stata (version 13.0, Stata Corp LP, College Station, TX, USA).

Results
=======

Literature search
-----------------

A total of 1,507 citations were identified in the initial search. Among these, 1,443 were excluded after removing duplicates, articles without examining research question, nonclinical studies, reviews, comments, and case reports. Sixty-four potentially relevant studies were retrieved for full-text review. Among them, nine studies were excluded for not including the control group; 14 for failing to meet the inclusion criteria; six for inappropriate grouping; 13 for insufficient outcome data; and seven for being previous versions of included studies. The selection process and list of full-text excluded articles are shown in [Figure 1](#f1-cmar-11-587){ref-type="fig"} and the [Supplementary materials](#SD1-cmar-11-587){ref-type="supplementary-material"}, respectively. In all, 15 studies[@b9-cmar-11-587]--[@b23-cmar-11-587] (one article reported EBRT vs RP and BT vs RP, thus being set as two studies for calculation) met the inclusion criteria and were included in the current meta-analysis. Of note, we identified seven articles[@b12-cmar-11-587],[@b24-cmar-11-587]--[@b29-cmar-11-587] derived from the US surveillance, epidemiology, and end results (SEER) cohort and two articles[@b8-cmar-11-587],[@b21-cmar-11-587] derived from the Japan Kyushu University Hospital in our literature search. These cohort studies overlapped the study population and outcomes, thus we only included the later or representative study[@b12-cmar-11-587],[@b21-cmar-11-587] to prevent the duplication of patients and study intervals. The information of the remaindered cohort studies from SEER and Kyushu University Hospital were shown in the bottom of [Table 1](#t1-cmar-11-587){ref-type="table"}.

Study characteristic
--------------------

The 15 included studies, published between 2002 and 2017, were all cohort designed. Of the 15 studies, nine were conducted in America,[@b9-cmar-11-587]--[@b14-cmar-11-587],[@b16-cmar-11-587],[@b17-cmar-11-587],[@b19-cmar-11-587] three in Europe,[@b15-cmar-11-587],[@b18-cmar-11-587],[@b22-cmar-11-587] and three in Asia.[@b20-cmar-11-587],[@b21-cmar-11-587],[@b23-cmar-11-587] Among all the included studies, a total of 619,479 individuals (mean age 60--73.6 years) were enrolled, 206,852 of whom were PCa patients who received RT, while the remaining 412,627 subjects were PCa patients who received RP treatment or non-RT. Of these included studies, two compared RT vs non-RT, eight compared RT vs RP, three compared EBRT vs RP, and three compared BT vs RP. The lag period varied between the included studies, ranging from 6 months to 10 years. The median length of follow-up ranged from 6 months to 20 years. Four studies reported the adjusted HR of the cohort study. The detail data of the included studies were summarized in [Table 1](#t1-cmar-11-587){ref-type="table"}.

Study quality and the overall quality of the evidence
-----------------------------------------------------

Using the NOS, 12 studies[@b11-cmar-11-587]--[@b20-cmar-11-587],[@b22-cmar-11-587],[@b23-cmar-11-587] were considered high quality and three studies[@b9-cmar-11-587],[@b10-cmar-11-587],[@b21-cmar-11-587] were judged medium quality ([Table S2](#SD4-cmar-11-587){ref-type="supplementary-material"}). The GRADE-relevant outcomes demonstrated that the rate of events of secondary BLCa on average in patients who received RT for PCa was 2,462/183,669 (1.3%), whereas in subjects who underwent RP or without RT was 4,263/382,761 (1.1%); the absolute effect of RT on secondary BLCa was 7 more per 1,000 (from 4 more to 10 more); the overall quality of the evidence was judged as low ([Table 2](#t2-cmar-11-587){ref-type="table"}).

Synthesis of results
--------------------

On unadjusted analysis of the studies with no restriction to lag period, synthesis of results showed that patients who received RT for PCa were significantly associated with an increased risk of BLCa (16 studies; HR=1.6, 95%CI: 1.33--1.92, *P*\<0.001; heterogeneity: *I*^2^=83.6%, *P*\<0.01) ([Figure 2](#f2-cmar-11-587){ref-type="fig"}). The outcomes were similar when restricted to a 5-year lag period (four studies; HR=1.84, 95%CI: 1.26--2.69, *P*=0.002; heterogeneity: *I*^2^=76.6%, *P*=0.005) ([Figure S1](#SD2-cmar-11-587){ref-type="supplementary-material"}), while no positive association between RT and secondary BLCa was found when restricted to a 10-year lag period (four studies; HR=1.93, 95%CI: 0.9--4.16, *P*=0.093; heterogeneity: *I*^2^=93.8%, *P*\<0.001) ([Figure S2](#SD2-cmar-11-587){ref-type="supplementary-material"}). After multivariable adjustment, the combined results revealed that PCa patients who received RT had a significantly higher risk of BLCa than the non-RT subjects (HR=1.96, 95%CI: 1.47--2.62, *P*\<0.001; heterogeneity: *I*^2^=61.4%, *P*=0.051) ([Figure S3](#SD2-cmar-11-587){ref-type="supplementary-material"}).

Subgroup analyses
-----------------

To further elicit the association between RT for PCa and the risk of BLCa and explore the great heterogeneity, subgroup analyses were performed subsequently based on the type of RT, age, geographical area, number of patients, and median follow-up ([Table 3](#t3-cmar-11-587){ref-type="table"}). Stratified analysis by the type of RT revealed that both RT without further specification (without reported outcomes of the specific form of RT in some included studies) and EBRT exhibited increased odds of BLCa compared with no RT (HR=1.79, 95%CI: 1.35--2.37;HR=1.27, 95%CI: 1.2--1.34), whereas when limited to BT did not show this association (HR=1.33, 95%CI: 0.87--2.05). Furthermore, no substantial heterogeneity was detected in EBRT and BT subgroup (*I*^2^=0%, and 12.3%, respectively) ([Figure 3](#f3-cmar-11-587){ref-type="fig"}).

Although there is evidence of the RT in causing secondary BLCa overall (pooled HR=1.6, 95%CI: 1.33--1.92), subgroup analyses showed that compared with RP or non-RT, RT did not significantly increase the occurrence of secondary BLCa for any of the subgroups, i.e., Europe (three studies;[@b15-cmar-11-587],[@b18-cmar-11-587],[@b22-cmar-11-587] HR=1.45, 95%CI: 0.76--2.76, *P*=0.261), Asia (three studies;[@b20-cmar-11-587],[@b21-cmar-11-587],[@b23-cmar-11-587] HR=1.57, 95%CI: 0.56--4.44, *P*=0.394), and median follow-up \<5 years (four studies;[@b11-cmar-11-587],[@b20-cmar-11-587],[@b21-cmar-11-587],[@b23-cmar-11-587] HR=1.55, 95%CI: 0.79--3.06, *P*=0.202) ([Table 3](#t3-cmar-11-587){ref-type="table"}).

Sensitivity analysis
--------------------

Sensitivity analysis was performed to evaluate the influence of individual study on the overall risk of BLCa. There was no substantial change on the overall combined HRs, which ranged from 1.52 (95%CI: 1.27--1.83) to 1.68 (95%CI: 1.39--2.02) after excluding any of the studies ([Table 4](#t4-cmar-11-587){ref-type="table"} and [Figure S4](#SD2-cmar-11-587){ref-type="supplementary-material"}). In addition, similar heterogeneity was found after each exclusion, the *I*^2^ ranged from 78.7% to 84.7%. The results demonstrated that no single study dominated the combined HRs and heterogeneity.

Publication bias
----------------

Nonsignificant publication bias among the studies was found and confirmed using the Begg's rank correlation test and Egger's linear regression (Begg's, *P* \>\|z\|=0.753; Egger, *P* \>\|t\|=0.172, 95%CI: --0.57--2.88) ([Figure S5](#SD2-cmar-11-587){ref-type="supplementary-material"}).

Discussion
==========

It was suggested that the mutagenic potential of ionizing radiation of RT results in the development of second malignancy, especially in the adjacent organ of the prostate, such as the bladder. Over the past few decades, a growing number of cohort studies have examined the association between RT for PCa and risk of secondary BLCa but provided inconsistent results. Based on data from 15 relevant cohort studies, the current meta-analysis indicates that RT for PCa is associated with secondary BLCa compared to RP treatment or no radiotherapy. PCa patients who received RT might have more than a 60% increase in the prevalence of secondary BLCa when compared to patients with non-RT. Ascertained by GRADEpro, the rate of events of BLCa on average in patients with RT for prostate cancer and non-RT subjects was 1.3% and 1.1%, respectively. These results were in line with some pertinent studies, which reported the suspicious association between RT for prostate cancer and BLCa but failed to meet our predefined eligibility criteria.[@b3-cmar-11-587],[@b8-cmar-11-587],[@b24-cmar-11-587]--[@b30-cmar-11-587] Moreover, some researchers also found that there was a dose--response relationship between RT and BLCa.[@b31-cmar-11-587],[@b32-cmar-11-587] In our study, sensitivity analyses revealed that the quantification of the risk for the BLCa in patients with RT for prostate cancer remained prominently higher in nearly all of the included studies, indicating that our findings were robust. We acknowledged that substantial heterogeneity has also been presented in the current meta-analysis. The lag time duration, the different types of RT, the chosen dose of RT, geographical area, median follow-up, adjustment factors, comorbidity, and varied characteristics of subjects could all be partly responsible for the obvious heterogeneity.

The results of the present study were similar with a meta-analysis reported by Wallis et al,[@b30-cmar-11-587] who found that there was a significantly increased risk of BLCa (adjusted HR=1.67, 95%CI: 1.55--1.80) after RT compared with the risk in those unexposed to RT. Similarly, they also found this relationship when restricted to a 5-year lag period. Moreover, this positive association existed in the analysis of the 10-year lag period in their study, which was quite different from what we found in our study. This might contribute to the number of the included studies (Wallis' study: two studies; current study: four studies), and thus resulted in different overall HR. Another explanation for this inconsistency could be the long interval of time after treatment by RT or RP. It is known that most cancers were age-related factors. This is also likely valuable as the incidence of BLCa increases with aging. Thus, the prevalence of BLCa after a 10-year lag period between RT and RP corresponded closely to each other might probably be due to advanced age.

Although the current meta-analysis has linked RT for prostate cancer to secondary BLCa, it is noteworthy that a certain point in time for the BLCa detection was different among the included studies. It was suggested that the time (lag period) should elapse between the date of received RT intervention (the time of exposure to radiation) and the development of a secondary cancer, and that the tumor might be considered induced by the radiation.[@b33-cmar-11-587] According to the previous studies, the lag period has been defined as 5 years.[@b33-cmar-11-587],[@b34-cmar-11-587] In the current study, the combined HR from the four included studies provided the 5-year lag period and demonstrated that patients who underwent RT for prostate cancer had an elevated prevalence of secondary BLCa than those who received RP therapy or non-RT intervention. These findings suggested that the secondary BLCa might be induced by radiation. Interestingly, however, it was inconsistent with the above outcomes when restricted to a 10-year lag period. The four studies reporting the 10-year lag period showed no association between RT and secondary BLCa (HR=1.93, 95%CI: 0.9--4.16, *P*=0.093). Notably, two of four studies ascertained the relationship between RT and secondary BLCa, while the other two studies failed to find a positive association, thus a significant heterogeneity (*I*^2^=93.8%, *P*\<0.001) was found as expected. As a result, such evidence was low and further studies are still needed to validate this association. We also proceeded with subgroup analyses to investigate the degree to which potential confounders may influence our findings.

In the subgroup analysis on the type of RT, with the exception of RT without further specification of some included studies, a positive association between RT and BLCa was detected in the EBRT groups whereas no association was found in the BT groups. These results were consistent with a recent study developed by Cosset et al,[@b35-cmar-11-587] they failed to detect any excess risk of secondary BLCa associated with permanent BT with a median follow-up over 11 years. Within the EBRT category, intensity-modulated radiation treatment (IMRT), volumetric modulated arc therapy, 2D- and 3D-conformal X-ray therapy (2D/3D-CRT) are developed conformal RT modalities designed for reducing the local radiation-induced toxicities, but secondary radiation-induced bladder tumors were still occasionally reported by studies.[@b16-cmar-11-587],[@b19-cmar-11-587],[@b36-cmar-11-587],[@b37-cmar-11-587] It was reported that the risk of second malignancy differed remarkably between IMRT and conventional RT for PCa, as well as between different IMRT methods.[@b38-cmar-11-587] They found that the conservative maximum risk of secondary malignancy was 1.7%, 2.1% and 5.1% in conventional radiation, 10-MV X-rays, and 18-MV X-rays of IMRT, respectively. Proton therapy, an emerging treatment modality for EBRT, have consistently shown reduced secondary cancer risks compared with IMRT and 3D-CRT due to the reduction in the volume of normal tissues irradiated.[@b39-cmar-11-587]

However, some have even reported that the risk of developing a secondary cancer was lower with either low dose or high dose rate BT alone when compared to any EBRT technique.[@b30-cmar-11-587] When further focused on the dose of BT, Murray et al[@b40-cmar-11-587] revealed that PCa patients who received a low dose rate of BT resulted in lower BLCa risks than high dose rate. Taken together, it is likely to recommend younger and healthier patients who did not accept RP treatment for reasons to select BT.

Stratified analysis by median follow-up showed that follow-up over 5 years exhibited increased odds of BLCa after RT, while those limited to \<5 years did not show this association. As mentioned previously, secondary malignancies were defined as a minimum lag time of 5 years. Thus, researchers might not find such association within 5-year follow-up. Likewise, in a study with a 48-month median follow-up, Okajima et al[@b41-cmar-11-587] proved the observed incidence of BLCa after RT was higher than the estimated incidence, but not significantly.

It is reported that the incidence of BLCa, especially the muscle-invasive BLCa, increases steadily with age.[@b42-cmar-11-587] Consistent with subgroup analysis on age in the present study, we found that patients aged over 70 years had a higher risk of BLCa compared with those under 70 years old (HR: 1.77 vs 1.48). In stratified analysis of the geographical area, an association between BLCa and RT was observed in the US, whereas this association was not found in Europe and Asia. On account of only three studies being included in both Europe and Asia stratification, great existing heterogeneity (*I*^2^=93.3%, 88.5%) and without providing the adjusted HR, thus this evidence was less robust. When stratified by the total number of patients, higher odds was observed in the subgroup of over 10,000 participants than below 10,000 participants (HR: 1.76 vs 1.36). These outcomes might contribute to the propensity of large sample size within the studies, which affords a higher level of evidence, thus representing the actual incidence of BLCa after RT.

Since evidence has shown an association between RT and secondary primary BLCa, might be potentially life-threatening. Based on all available data related to the survival analysis of BLCa after RT, the evidence is still controversial. Of note, it has been reported that in patients with localized PCa, 10-year overall survival was higher in EBRT compared with RP treatment (89% vs 83%).[@b43-cmar-11-587] In the cases of treatment-induced secondary primary BLCa, it was suggested that RT was correlated with poor survival compared to surgical therapy for PCa patients. According to the studies developed by Shiota et al,[@b8-cmar-11-587],[@b21-cmar-11-587] 5-year and 10-year BLCa-free survival of the PCa patients was 97.3% and 99.4%, and 91.3% and 97.4% for EBRT and RP treatment, respectively. These results agreed with the data of Bhojani et al:[@b13-cmar-11-587] patients treated with RT and surgical therapy enabled 10-year BLCa-free survival rate of 96.2% and 97.3%, respectively. Furthermore, Abern et al[@b28-cmar-11-587] reported that prior RT for PCa was associated with decreased BLCa-specific survival compared to RP treatment. Interestingly, however, these findings contrast with reports in which patients with PCa who underwent RT were found to have a higher secondary BLCa survival rate compared with RP therapy. Boorjian et al[@b11-cmar-11-587] reported that patients who received RT and RP therapy presented 5-year BLCa-free survival of 99.1% and 98.5%, respectively. Singh et al[@b12-cmar-11-587] analyzed over 120,000 men who received RT treatment and 230,000 men with RP therapy for PCa from the SEER database. They found that the number of secondary BLCa deaths was 268/1,836 (14.6%) and 510/2,753 (22.9%) in EBRT and RP treatment cohorts, respectively. This is in line with the finding of Hamilton et al[@b17-cmar-11-587] that deaths from secondary BLCa between BT and RP therapy were 5/33 (15%) and 9/32 (28%), respectively.

In this study, we have investigated the potential association between RT and secondary BLCa based on all available evidence published in recent years. We have acknowledged some inherent limitations to our study. First, although all the included studies have defined the secondary malignancies as 5 years after radiation within their studies, only four studies provided the data of 5-year, 10-year lag period. Thus, future studies with over 5-year lag period are required to validate the evidence of RT predisposing to the development of secondary BLCa. Second, it is known that the confounding factors (ie, age, smoking, comorbidities, and other risk factors) could modulate the secondary BLCa risk. However, multivariable adjustments of HRs were only available in four studies. Third, lack of radiotherapy dose and retrospective nature of data used in the analysis with lack of robust long-term follow-up to assess the incidence of BLCa following radiotherapy should also be considered as limitations of the present study. Fourth, we have observed substantial heterogeneity across included studies. Therefore, subgroup analysis and sensitivity analyses were subsequently performed to explore the potential causes of the heterogeneity. And we found that no significant heterogeneity was detected when we performed the stratification analyses in EBRT and BT subgroups.

Conclusion
==========

Our study indicates a higher hazardous effect of RT for developing secondary BLCa compared to RP or non-RT. It is important to note that no such association was observed between BT and secondary BLCa. Though there was an increased risk of BLCa after RT, the absolute rates remained low. And whether the secondary BLCa serves as a life-threatening complication is still controversial.
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Characteristics of the included studies

  Study                                                                                                                                            Study design   Data source (study interval)                               Lag time                                                Follow-up                       Mean age (years)                  Study group (S) case/total                                                                          Control group (C) case/total                                                                            HR (95%CI)                                                                                                     Survival information
  ------------------------------------------------------------------------------------------------------------------------------------------------ -------------- ---------------------------------------------------------- ------------------------------------------------------- ------------------------------- --------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  Pickles and Phillips[@b9-cmar-11-587] 2002 Canada                                                                                                Cohort         British Columbia cancer agency (1984--2000)                NA                                                      S: 5.3 years C: 3.1 years       All: 71.5                         RT 343/25,569                                                                                       Non-RT 506/71,242                                                                                       1.89 (1.65, 2.16)                                                                                              NA
  Singh[@b10-cmar-11-587] 2005 US                                                                                                                  Cohort         Veterans Affairs Medical Center (1996--2003)               Over 6 months                                           NA                              All: 68.2                         RT 8/210                                                                                            Without RT 7/416                                                                                        2.26 (0.83, 6.16)                                                                                              NA
  Boorjian et al[@b11-cmar-11-587] 2007 US                                                                                                         Cohort         CaPSURE (1989--2003)                                       NA                                                      Median 39 months                All: 70                           RT 33/2,741                                                                                         RP 37/4,608                                                                                             Crude: 1.50 (0.94, 2.39) Adjust: 1.59 (0.97, 2.6)                                                              \% 5-year BLCa-free survival (95%CI): S: 99.1 (98.5--99.5) C: 98.5 (97.3--99.1)
  Singh et al[@b12-cmar-11-587] 2010 US                                                                                                            Cohort         SEER (1973--2005)                                          5 years 10 years                                        S: 63.7 months C: 75.2 months   S: 69.4±7.6 C: 66.9±9.8           EBRT No restriction to lag time: 1,836/124,141 5 years lag: 748/123,053 10 years lag: 207/122,512   Surgery No restriction to lag time: 2,753/23,5341 5 years lag: 1076/233,844 10 years lag: 429/233,197   No restriction to lag time: 1.26 (1.19, 1.34) 5 years lag: 1.32 (1.20, 1.45) 10 years lag: 0.92 (0.78, 1.08)   Number of BLCa deaths (%): S: 268 (14.6%) C: 510 (22.9%)
  Bhojani et al[@b13-cmar-11-587] 2010 Canada                                                                                                      Cohort         The Quebec Health Plan (1983--2003)                        5 years 10 years                                        5--20 years                     S: 69.6 C: 64.6                   EBRT NA/9,390                                                                                       RP NA/8,455                                                                                             Adjust: 5 years lag: 1.50 (1.10, 2.04) 10 years lag: 2.0 (0.88, 4.57)                                          \% 10-year BLCa-free survival S: 96.2 C: 97.3
  Huang et al[@b14-cmar-11-587] 2011 US                                                                                                            Cohort         William Beaumont Hospital (1984-- 2005)                    5 years 10 years                                        S: 9.26 years C: 9.19 years     S: 71 C: 70                       RT NA/2,120                                                                                         Surgery NA/2,120                                                                                        Overall: 2.02 (1.20, 3.41) 5 years lag: 4.49 (1.70, 11.85) 10 years lag: 9.70 (1.23, 76.57)                    NA
  Hinnen et al[@b15-cmar-11-587] 2011 Netherlands                                                                                                  Cohort         Netherlands Cancer Institute (1989-- 2005)                 NA                                                      S: 7.1 years C: 8.7 years       All: 64.7                         Brachytherapy 17/1,187                                                                              RP 10/701                                                                                               1.00 (0.46, 2.18)                                                                                              NA
  Zelefsky et al[@b16-cmar-11-587] 2012 US                                                                                                         Cohort         Memorial Sloan-Kettering Cancer Center (1998--2001)        EBRT: median 49 months lag RP: median 98 months lag     S: 90 months C: 113 months      S: ≥65 (74.1%) C: ≥65 (23.0%)     EBRT 12/897                                                                                         RP 16/1,348                                                                                             1.13 (0.54, 2.37)                                                                                              NA
  Zelefsky et al[@b16-cmar-11-587] 2012 US                                                                                                         Cohort         Memorial Sloan-Kettering Cancer Center (1998--2001)        EBRT: median 39.5 months lag RP: median 98 months lag   S: 92 months C: 113 months      S: ≥65 (59.8%) C: ≥65 (23.0%)     Brachytherapy 4/413                                                                                 RP 16/1,348                                                                                             0.82 (0.27, 2.43)                                                                                              NA
  Hamilton et al[@b17-cmar-11-587] 2014 Canada                                                                                                     cohort         British Columbia Cancer Agency (1998--2010)                Median time to second BLCa: 4.2 years                   S: 5.8 years C: 6.4 years       S: 60--70 years C: 57--66 years   Brachytherapy 33/2,418                                                                              RP 32/4,015                                                                                             1.71 (1.06, 2.78)                                                                                              Death from secondary BLCa: S: 5/33 (15%); C: 9/32 (28%)
  Van Hemelrijck et al[@b18-cmar-11-587] 2014 Switzerland                                                                                          Cohort         Cancer Registry Zurich and Zug (1980--2010)                Over 6 months                                           NA                              All: 71.65±9.2                    RT 179/1,577                                                                                        Surgery 554/5,381                                                                                       1.10 (0.94, 1.29)                                                                                              NA
  Nam et al[@b19-cmar-11-587] 2014 US                                                                                                              Cohort         Ontario Health Insurance Plan (2002--2009)                 5 years                                                 over 1 year                     S: 69.4 C:61.5                    RT 45/16,595                                                                                        Surgery 15/15,870                                                                                       2.87 (1.60, 5.14)                                                                                              NA
  Joung et al[@b20-cmar-11-587] 2015 Korea                                                                                                         Cohort         Korean Central Cancer Registry (1993--2011)                3.3 years                                               42 months                       60--79 years                      RT 13/3,407                                                                                         Surgery 155/27,765                                                                                      0.68 (0.39, 1.20)                                                                                              NA
  Shiota et al[@b21-cmar-11-587] 2016 Japan                                                                                                        Cohort         Kyushu University Hospital (2000-- 2013)                   NA                                                      S: 4.3 years C: 3.1 years       S: 71 (67--76) C: 65 (60--69)     RT 14/631                                                                                           Surgery 5/437                                                                                           1.94 (0.70, 5.34)                                                                                              \% 5-year BLCa-free survival S: 97.3 C: 99.4
  Hegemann et al[@b22-cmar-11-587] 2017 Germany                                                                                                    Cohort         Munich Cancer Registry (1988--2008)                        10 years                                                S: 9.6 years C: 10.2 years      S: 65.2 C: 70.3                   RT 105/3,883                                                                                        RP 157/14,289                                                                                           Crude: 2.46 (1.93, 3.14) Adjusted: 2.10 (1.59, 2.78)                                                           NA
  Fan et al[@b23-cmar-11-587] 2017 Chinese Taipei                                                                                                  Cohort         National Health Insurance Research Database (2000--2010)   NA                                                      4.40±3.05 years                 all: 73.6                         RT NA/11,673                                                                                        ADT or RP NA/19,291                                                                                     No crude HR adjusted: 2.96 (1.97, 4.43)                                                                        NA
  **Some cohorts derived from the same population-based database (ie, SEER, Kyushu University Hospital), thus not for combining the overall HR**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Pawlish et al[@b24-cmar-11-587] 1997 US                                                                                                          Cohort         SEER (1973--1982)                                          NA                                                      Median 6.1 years                S: 67.3 C: 72.3                   RT NA/2,308                                                                                         No RT NA/7,481                                                                                          1.59 (1.09, 2.32)                                                                                              NA
  Moon et al[@b25-cmar-11-587] 2006 US                                                                                                             Cohort         SEER (1973--1999)                                          5 years                                                 Median 6.4 years                All: 70.0±7.4                     EBRT 568/39,805                                                                                     No RT 815/94,541                                                                                        1.66 (1.49, 1.85)                                                                                              NA
  Abdel-Wahab et al[@b26-cmar-11-587] 2007 US                                                                                                      Cohort         SEER (1988--2002)                                          5 years                                                 S: 5.3 years C: 4.3 years       S: 70.5±6.9 C: 73.1±9.0           EBRT 710/48,400                                                                                     No RT, no surgery 372/40,733                                                                            1.61 (1.42, 1.82)                                                                                              NA
  Nieder et al[@b27-cmar-11-587] 2008 US                                                                                                           Cohort         SEER (1988--2003)                                          NA                                                      49 months                       S: ≥60 (91.89%) C: ≥60 (68.15%)   EBRT NA/9,3059                                                                                      RP NA/109,178                                                                                           1.88 (1.70, 2.08)                                                                                              NA
  Abern et al[@b28-cmar-11-587] 2013 US                                                                                                            Cohort         SEER (1988--2007)                                          NA                                                      Median 65 months                NA                                RT 2,135/149,158                                                                                    RP 942/126,042                                                                                          1.92 (1.77, 2.07)                                                                                              BLCa specific survival (RP vs RT): HR (95%CI)=1.38 (1.10--1.72)
  Davis et al[@b29-cmar-11-587] 2014 US                                                                                                            Cohort         SEER (1992--2010)                                          NA                                                      2-over 120 months               All: 65--74                       EBRT 343/25,569                                                                                     No RT 506/71,242                                                                                        1.89 (1.65, 2.16)                                                                                              NA
  Shiota et al[@b8-cmar-11-587] 2015 Japan                                                                                                         Cohort         Kyushu University Hospital (2000-- 2012)                   52.3 months                                             S: 51.2 months C: 44.8 months   S: 70 (65--74) C: 65 (60--69)     EBRT 11/348                                                                                         RP 5/437                                                                                                2.76 (0.97, 7.88)                                                                                              \% 10-year BLCa-free survival S: 91.3 C: 97.4

**Abbreviations:** RT, radiotherapy; EBRT, external beam radiotherapy; BLCa, bladder cancer; RP, radical prostatectomy; NA, not available; SEER, the US surveillance, epidemiology, and end results.

###### 

GRADE summary of evidence for the effects of radiotherapy for prostate cancer on secondary bladder cancer

  Quality assessment                                                  No. of patients         Effect                                               Quality                                              Importance                                                                                                                                                                                                                                                                                                                                          
  ------------------------------------------------------------------- ----------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------- ---------------------- --------------------- ------------------------------------------- ----- ----------
  Secondary bladder cancer (follow-up: median 6 months to 20 years)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  16                                                                  Observational studies   Serious[a](#tfn3-cmar-11-587){ref-type="table-fn"}   Serious[b](#tfn4-cmar-11-587){ref-type="table-fn"}   No serious indirectness[c](#tfn5-cmar-11-587){ref-type="table-fn"}   Serious[d](#tfn6-cmar-11-587){ref-type="table-fn"}   Very strong association^e^ increased effect for HR \~1[f](#tfn8-cmar-11-587){ref-type="table-fn"}   2,462/183,669 (1.3%)   4,263/382,761 (1.1%)   HR 1.6 (1.33--1.92)   7 more per 1,000 (from 4 more to 10 more)   Low   Critical

**Notes:** GRADE Working Group grades of evidence. High quality: further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the estimate.

Selection bias, performance bias, and detection bias were detected in some studies.

Inconsistent association between radiotherapy and secondary bladder cancer was reported in some included studies.

Some included studies suggested the confounders and comorbidities and other risk factors might associated with bladder cancer.

Some included studies failed to adjust the confound factors, such as age, smoking, etc.

A total of 619,479 participants from 16 studies were included, the combined HR was 1.6 (95%CI: 1.33--1.92, *P*=0.001).

After multivariable adjustment, the combined HR for bladder cancer was increased (HR=1.96, 95%CI: 1.47--2.62, *P*=0.000).

###### 

Subgroup analysis of the association between RT and secondary BLCa

  Category of variables                No. of studies   Heterogeneity   Random-effects model                       
  ------------------------------------ ---------------- --------------- ---------------------- ------------------- ---------
  Radiotherapy without specification   10               85.3            0.000                  1.79 (1.35--2.37)   \<0.001
   EBRT                                3                0.0             0.528                  1.27 (1.20--1.34)   \<0.001
   Brachytherapy                       3                12.3            0.32                   1.33 (0.87--2.05)   0.188
  Median follow-up                                                                                                 
   \<5 years                           4                83.1            0.000                  1.55 (0.79--3.06)   0.202
   ≥5 years                            9                85.8            0.000                  1.59 (1.26--2.02)   \<0.001
  Age                                                                                                              
   \<70 years                          10               79.5            0.000                  1.48 (1.13--1.94)   0.005
   ≥70 years                           6                86.4            0.000                  1.77 (1.27--2.46)   0.001
  Geographical area                                                                                                
   America                             10               78.2            0.000                  1.62 (1.31--2.00)   \<0.001
   Europe                              3                93.3            0.000                  1.45 (0.76--2.76)   0.261
   Asia                                3                88.5            0.000                  1.57 (0.56--4.44)   0.394
  No. of patients                                                                                                  
   \<10,000                            9                26.1            0.212                  1.36 (1.10--1.67)   0.004
   ≥10,000                             7                92.2            0.000                  1.76 (1.32--2.34)   \<0.001

**Abbreviations:** EBRT, external beam radiotherapy; BLCa, bladder cancer; RT, radiotherapy.

###### 

Sensitivity analysis after each study was excluded by turns

  Study omitted                                  HR (95%CI) for remainders   Heterogeneity   
  ---------------------------------------------- --------------------------- --------------- ---------
  Pickles and Phillips (2002)[@b9-cmar-11-587]   1.57 (1.29--1.91)           79.3            \<0.001
  Singh et al (2005)[@b10-cmar-11-587]           1.58 (1.31--1.91)           84.5            \<0.001
  Boorjian et al (2007)[@b11-cmar-11-587]        1.60 (1.32--1.95)           84.7            \<0.001
  Singh et al (2010)[@b12-cmar-11-587]           1.63 (1.31--2.03)           78.7            \<0.001
  Bhojani et al (2010)[@b13-cmar-11-587]         1.60 (1.31--1.96)           84.6            \<0.001
  Huang et al (2011)[@b14-cmar-11-587]           1.57 (1.30--1.90)           84.3            \<0.001
  Hinnen et al (2011)[@b15-cmar-11-587]          1.62 (1.34--1.96)           84.6            \<0.001
  Zelefsky et al (2012)[@b16-cmar-11-587]        1.62 (1.34--1.96)           84.6            \<0.001
  Zelefsky et al (2012)[@b16-cmar-11-587]        1.62 (1.34--1.96)           84.5            \<0.001
  Hamilton et al (2014)[@b17-cmar-11-587]        1.59 (1.31--1.93)           84.6            \<0.001
  Van et al (2014)[@b18-cmar-11-587]             1.66 (1.35--2.04)           83.1            \<0.001
  Nam et al (2014)[@b19-cmar-11-587]             1.55 (1.28--1.86)           83.6            \<0.001
  Joung et al (2015)[@b20-cmar-11-587]           1.68 (1.39--2.02)           83.6            \<0.001
  Shiota et al (2016)[@b21-cmar-11-587]          1.59 (1.31--1.92)           84.6            \<0.001
  Hegemann et al (2017)[@b22-cmar-11-587]        1.53 (1.27--1.83)           79.7            \<0.001
  Fan et al (2017)[@b23-cmar-11-587]             1.52 (1.27--1.83)           82.0            \<0.001

[^1]: These authors contributed equally to this work
